Adjuvant BEP for 1 Cycle Safe, Efficacious for Testicular Cancer

Share this content:
Bleomycin, etoposide, and cisplatin for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.
Bleomycin, etoposide, and cisplatin for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.

ORLANDO, FL Bleomycin, etoposide, and cisplatin (BEP) for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP for 2 cycles among patients with high-risk stage 1 non-seminomatous or combined germ cell tumors of the testis (NSGCTT), according to a study presented at the 2017 Genitourinary Cancers Symposium.1

"The standard adjuvant chemotherapy regimen for patients with high-risk stage 1 NSGCTT is surveillance until recurrence with BEP for 3 cycles at the time of recurrence or adjuvant BEP for 2 cycles with etoposide given at a dose of 360 mg/m2," explained Robert Huddart, PhD, chair of the Institute of Cancer Research in Sutton, England. "Adjuvant chemotherapy has a 2-year recurrence-free rate of 98% and avoids intensive surveillance, but delivers 33% more chemotherapy cycles on a population basis."

For the open-label, non-randomized, phase 3 trial (ClinicalTrials.gov Identifier: NCT01726374), investigators enrolled 264 post-orchiectomy patients vascular invasion-positive stage 1 NSGCTT or combined seminoma and NSGCT, as well as normal tumor markers.

"This study used a novel design to investigate a new treatment approach for an uncommon cancer," Dr Huddart added.

Participants received 1 cycle of bleomycin 30,000 IU IV on days 1, 8, and 15, plus etoposide 165 mg/m2 IV on days 1, 2, and 3, and cisplatin 50 mg/m2 IV on days 1 and 2. To reduce the risk for neutropenic sepsis, all participants received prophylactic fluoroquinolone and granulocyte colony-stimulating factor.

The 2-year recurrence rate was 1.3% (95% CI, 0.4-4.0) among the 236 evaluable patients. All 4 patients who developed malignant recurrence subsequently received second-line chemotherapy with or without surgery, with only 1 dying at month 9 due to refractory disease. Two-year overall survival was 99.0% (95% CI, 96.6-99.8).

"The 2-year recurrence rate is similar to that seen with BEP for 2 cycles," said Dr Huddart.

Investigators also observed 3 instances of non-malignant recurrences with teratoma differentiated in retroperitoneal nodes. All of these patients successfully underwent retroperitoneal lymph node dissection and are now free of disease.

RELATED: TP53, MDM2 Alterations Linked to Cisplatin Resistance in Testicular Cancer

About 40% of patients developed grade 3 to 4 adverse events.

"This provides robust evidence to inform the decision between adjuvant chemotherapy and surveillance," said Dr Huddart. "Adoption of BEP for 1 cycle as a standard of care would reduce overall exposure to chemotherapy in this young population."

Reference

  1. Huddart RA, Joffe JK, White JD, et al. 111: A single-arm trial evaluating one cycle of BEP as adjuvant chemotherapy in high-risk, stage 1 non-seminomatous or combined germ cell tumors of the testis (NSGCTT). Paper presented at: 2017 Genitourinary Cancers Symposium; February 16-18, 2017; Orlando, FL.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs